Mithra Announces Commercial Launch of Myring™ in Belgium

  • Mithra’s hormonal contraceptive ring is now available in pharmacies in Belgium under the trademark name Myloop®
  • Large-scaled global commercialization of Myring™, especially in the world’s three largest markets
  • Mithra CDMO in Belgium expected to produce nearly 2 million rings in 2020

Liege, Belgium, 12 February 2020 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the commercial launch of Myring™ in Belgium. The Belgian contraceptive ring market is valued at around EUR 5.1 million, with more than 600,000 rings sold each year. Mithra’s vaginal contraceptive ring is marketed by Ceres Pharma in Belgium under the trademark name Myloop®.

Mithra receives positive ruling on Patent Income Deduction

Liege, Belgium, 10 February 2020 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has received a positive ruling from the Belgian tax authorities, enabling Mithra to benefit from the Belgian Patent Income Deduction (PID) 1 on patent related income arising from Mithra’s E4-based products (Estelle®, Donesta®).

Statement from the CEO and the Board of Directors of Mithra following the articles published in the Belgian press

Liege, Belgium, 23 January 2020 – Following publications in the press on Wednesday, 22 January 2020 regarding an alleged insider trading offence attributed to Mr. François Fornieri, CEO of Mithra Pharmaceuticals, Mr. Fornieri vigorously contests any involvement in any such offence and deeply regrets the prejudice caused by this alleged information to Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health.

Mithra Signs LSA for Commercialization of Myring™ in Italy, the Third Biggest Worldwide Market

  • Mithra grants a license to Farmitalia for commercialization of its vaginal contraceptive ring in Italy
  • Italy is the third largest worldwide contraceptive ring market with nearly 2 million vaginal rings sold per year
  • Mithra CDMO will launch the production of nearly 20,000 rings per month for the Italian market in the coming weeks

Liege, Belgium, 21 January 2020 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has entered into a license and supply agreement with Farmitalia for the commercialization of its hormonal contraceptive ring Myring™ in Italy.

Mithra Announces 2020 Financial Calendar

Liege, Belgium, 15 January 2020 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company focused on women’s health, today announces its financial calendar for 2020 :

  • 9 March 2020 : 2019 Full Year Results
  • 22 April 2020 : 2019 Annual Report
  • 22 May 2020 : Annual General Shareholders Meeting
  • 24 September 2020 : 2020 Interim report

This calendar and all corporate information on the Company, such as its financial statements, events or corporate presentations, is available on the Company’s website in the Investors’ section (investors.mithra.com).

E4 Paves the Road Towards a Revolutionary Era of Environmental Friendly Medicines

  • Estelle® to be the 1st Combined Oral Contraceptive (COC) based on an environmental friendly estrogen (E4)
  • Environmental Risk Assessment study demonstrates absence of environmental risk for Estetrol (E4)
  • E4 endocrine disruptive effects on the environment are insignificant in comparison to currently marketed estrogens commonly found in the aquatic environment
  • E4 will contribute to preserve intact ground and surface waters and ecosystems in line with UN 2030 sustainable development goals
Liege, Belgium, 10 January 2020 – 7:30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that data from a recent environmental assessment study shows that Estetrol (E4) is significantly more environmentally-friendly compared to alternatives currently on the market.

Mithra Signs License and Supply Agreement for Commercialization of Tibelia® in Italy

  • Mithra grant a license to Farmitalia for commercialization of its hormone treatment Tibelia® in Italy
  • Tibelia® is currently marketed in 13 countries through existing license and supply agreements
Liege, Belgium, 07 January 2020 – 7 :30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has entered into a license and supply agreement with Farmitalia for the commercialization of Tibelia® in Italy.

Mithra Signs LSA with Alvogen for Commercialization of Estelle® in Hong Kong and Taiwan

  • Mithra grants exclusive license to Alvogen for commercialization of its combined oral contraceptive Estelle® in Hong Kong and Taiwan
  • Agreement follows licensing deals for Estelle® with market leaders in U.S., Europe, Russia, Canada, Brazil, Japan, South Korea, Middle East and South Africa
Liege, Belgium, 6 January 2020 – 7 :30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has signed an exclusive license and supply agreement with Alvogen for the commercialization of Estelle® in Hong Kong and Taiwan. Estelle® is Mithra’s novel combined oral contraceptive (COC) product candidate, containing 15 mg Estetrol (E4) and 3 mg drospirenone (DRSP).

First patient recruited for Donesta® Phase III Clinical Study in Europe

  • Recruitment of the first patient for the second pivotal Donesta® Phase III study conducted in 12 countries in Europe, Russia and South America
  • “E4 Comfort” Phase III Clinical Program for Donesta® successfully launched in October 2019 with recruitment of first patient for North American study
  • Phase III Program aimed at enrolling approximately 2200 menopausal women with vasomotor symptoms
Liege, Belgium, 31 December 2019 – 7:30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the recruitment of the first patient for the second pivotal Phase III Donesta® clinical study. Donesta® is a next generation orally-administered E4-based hormone therapy product candidate for the relief of menopausal vasomotor symptoms (VMS).

Information on the Total Number of Voting Rights (Denominator)

Liege, Belgium, 24 December 2019 – 07:30 CET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Mithra Pharmaceuticals SA announces the following information, following the issuance of 1,444,250 new shares on 20 December 2019, in execution of the principle agreement concluded on 30 September with the former owners of Uteron Pharma relating to the remaining payment obligations that Mithra has under the current earnout agreement.